1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
298 articles with CSL Behring
12/7/2021Life sciences professionals are mixed as to whether the job market is in favor of the candidate or the employer. However, life sciences employers aren’t.
HCmed Innovations, a Taiwanese company that focuses on the development of vibrating mesh nebulizers, announced the successful completion of the first developmental milestone for the collaboration agreement with CSL Behring.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
CSL's Global Chief Human Resources Officer Elizabeth Walker has been appointed to the Urban League of Philadelphia's Board of Directors.
FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience
CSL Behring received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020 ) for co-packaging of a convenience administration kit along with its product BERINERT.
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
5/24/2021It was another busy week for clinical trial announcement. Here’s a look.
New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
Global biotherapeutics leader CSL Behring announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome.
Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, are excited to announce that Dr. Minnie Sarwal of NephroSant was selected as the winner of the Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation.
HAEGARDA® is now available in all of Canada for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
CSL Behring Canada announced that HAEGARDA®, is now available in all of Canada.
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
Global biotherapeutics leader CSL Behring announced the closing of its global Commercialization and License agreement with uniQure for etranacogene dezaparvovec, a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials and has been shown to result in near-normal levels of Factor IX – the blood clotting protein lacking in people with hemophilia B. CSL Behring has been recognized as a global hematology leader for decades.
HCmed announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring's plasma derived immunoglobulin administered via HCmed's new generation vibrating-mesh nebulizing device.
As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.
Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, announce the eleven patient entrepreneurs selected as finalists for the 2021 Innovation Challenge: Thriving with Transplantation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Industry-leading biotech CSL is leveraging its integrated global portfolio to bring urgently needed therapeutic COVID-19 treatments to patients around the world.
Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.
The filing to the U.S. District Court District of New Jersey, dated December 31st, 2020, states that the materials include compound data, strategic plans related to translational and biomarker data, therapeutic program reviews, abstract publications, plans for Congressional presentations, drug mo...
New Harris Poll Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy
CSL Behring, a global biotherapeutics leader, announced survey results showing that a vast majority of HAE patients say it's important their preventive therapy specifically corrects C1 esterase inhibitor deficiency.
Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
Global biotherapeutics leader CSL Behring announced a community partnership with six Urban League affiliates across the U.S., starting with the Urban League of Philadelphia.